Allo BMT in Advanced Leukemia or High Grade Lymphoma
This study has been completed.
Sponsor:
Stanford University
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186290
First received: September 13, 2005
Last updated: October 7, 2010
Last verified: October 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.
| Condition | Intervention |
|---|---|
|
Lymphoma, Non-Hodgkin Leukemia Blood and Marrow Transplant (BMT) Lymphomas: Non-Hodgkin |
Procedure: ablative allogeneic hematopoietic cell transplantation |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma |
Resource links provided by NLM:
Further study details as provided by Stanford University:
Primary Outcome Measures:
- overall survival [ Time Frame: october 2009 ] [ Designated as safety issue: No ]
- disease free survival [ Time Frame: October 2009 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- early and late toxicities of the treatment regimen [ Time Frame: October 2009 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 145 |
| Study Start Date: | December 1989 |
| Study Completion Date: | October 2009 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma
Eligibility| Ages Eligible for Study: | up to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:HLA identical donor
- adequate organ function
- other life threatening disease
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00186290
Locations
| United States, California | |
| Stanford University School of Medicine | |
| Stanford, California, United States, 94305 | |
Sponsors and Collaborators
Stanford University
Investigators
| Principal Investigator: | Robert Lowsky | Stanford University |
More Information
No publications provided
| Responsible Party: | Robert Lowsky, Stanford University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00186290 History of Changes |
| Other Study ID Numbers: | BMT34, 74165, BMT34 |
| Study First Received: | September 13, 2005 |
| Last Updated: | October 7, 2010 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Leukemia Lymphoma Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on June 18, 2013